377 related articles for article (PubMed ID: 22093324)
1. Antioxidants as therapeutic agents for liver disease.
Singal AK; Jampana SC; Weinman SA
Liver Int; 2011 Nov; 31(10):1432-48. PubMed ID: 22093324
[TBL] [Abstract][Full Text] [Related]
2. Chronic liver disease and oxidative stress - a narrative review.
Seen S
Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):1021-1035. PubMed ID: 34176419
[No Abstract] [Full Text] [Related]
3. [Silymarin in the treatment of chronic liver diseases: past and future].
Fehér J; Lengyel G
Orv Hetil; 2008 Dec; 149(51):2413-8. PubMed ID: 19073452
[TBL] [Abstract][Full Text] [Related]
4. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C].
Pár A; Róth E; Rumi G; Kovács Z; Nemes J; Mózsik G
Orv Hetil; 2000 Jul; 141(30):1655-9. PubMed ID: 10962902
[TBL] [Abstract][Full Text] [Related]
5. Advances in alcoholic liver disease.
Song Z; Joshi-Barve S; Barve S; McClain CJ
Curr Gastroenterol Rep; 2004 Feb; 6(1):71-6. PubMed ID: 14720457
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiological basis for antioxidant therapy in chronic liver disease.
Medina J; Moreno-Otero R
Drugs; 2005; 65(17):2445-61. PubMed ID: 16296871
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
Musso G; Anty R; Petta S
Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094
[TBL] [Abstract][Full Text] [Related]
8. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
Ji HF; Sun Y; Shen L
Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
[TBL] [Abstract][Full Text] [Related]
9. [Antioxidant therapy in chronic liver diseases].
Lengyel G; Tulassay Z
Orv Hetil; 2006 Jun; 147(24):1113-8. PubMed ID: 16865855
[TBL] [Abstract][Full Text] [Related]
10. The Role of Oxidative Stress and Antioxidants in Liver Diseases.
Li S; Tan HY; Wang N; Zhang ZJ; Lao L; Wong CW; Feng Y
Int J Mol Sci; 2015 Nov; 16(11):26087-124. PubMed ID: 26540040
[TBL] [Abstract][Full Text] [Related]
11. Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease.
Ore A; Akinloye OA
Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30682878
[TBL] [Abstract][Full Text] [Related]
12. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress.
Ferro D; Baratta F; Pastori D; Cocomello N; Colantoni A; Angelico F; Del Ben M
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32927776
[TBL] [Abstract][Full Text] [Related]
13. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
14. Vitamin E and nonalcoholic fatty liver disease.
Pacana T; Sanyal AJ
Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
[TBL] [Abstract][Full Text] [Related]
15. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
16. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
17. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH).
Takaki A; Kawai D; Yamamoto K
Int J Mol Sci; 2013 Oct; 14(10):20704-28. PubMed ID: 24132155
[TBL] [Abstract][Full Text] [Related]
18. Dietary supplementation in patients with alcoholic liver disease: a review on current evidence.
Ghorbani Z; Hajizadeh M; Hekmatdoost A
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):348-60. PubMed ID: 27498574
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence.
Zhu H; Jia Z; Misra H; Li YR
J Dig Dis; 2012 Mar; 13(3):133-142. PubMed ID: 22356308
[TBL] [Abstract][Full Text] [Related]
20. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
